{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:18:22Z","timestamp":1785784702877,"version":"3.56.0"},"reference-count":73,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2022,4,25]]},"DOI":"10.1272\/jnms.jnms.2022_89-221","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T22:12:13Z","timestamp":1637878333000},"page":"128-138","source":"Crossref","is-referenced-by-count":10,"title":["Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features"],"prefix":"10.1272","volume":"89","author":[{"given":"Akiko","family":"Tonooka","sequence":"first","affiliation":[{"name":"Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research"},{"name":"Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Komagome Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Integrated Diagnostic Pathology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18;432 (7015):294-7.","DOI":"10.1038\/nature03095"},{"key":"2","unstructured":"2. Moeckel GW, Kashgarian M, Racusen LC. Ischemic and toxic acute tubular injury and other ischemic renal injuries. In: Jannette JC, D'Agati DV, Olson JL, Silva FG, editors. Heptinstall's pathology of the kidney: Wolters Kluwer Health; 2014."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mehta RL, Awdishu L, Davenport A, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88 (2):226-34.","DOI":"10.1038\/ki.2015.115"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Capasso A, Benigni A, Capitanio U, et al. Summary of the international conference on onco-nephrology: an emerging field in medicine. Kidney Int. 2019;96 (3):555-67.","DOI":"10.1016\/j.kint.2019.04.043"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Perazella MA. Onco-nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7 (10):1713-21.","DOI":"10.2215\/CJN.02780312"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Perazella MA, Shirali AC. Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol. 2018;29 (8):2039-52.","DOI":"10.1681\/ASN.2018050488"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015 May 26;87 (5):909-17.","DOI":"10.1038\/ki.2015.30"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006 Sep;6 (9):714-27.","DOI":"10.1038\/nrc1913"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fan Q, Ma J, Zhang B, et al. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system. Cancer Chemother Pharmacol. 2020;86 (5):655-62.","DOI":"10.1007\/s00280-020-04151-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets. 2011 Dec;10 (6):497-508.","DOI":"10.2174\/187152811798104872"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zirlik K, Duyster J. Anti-Angiogenics: Current situation and future perspectives. Oncol Res Treat. 2018;41 (4):166-71.","DOI":"10.1159\/000488087"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ricci V, Ronzoni M, Fabozzi T. Aflibercept a new target therapy in cancer treatment: a review. Crit Rev Oncol Hematol. 2015 Dec;96 (3):569-76.","DOI":"10.1016\/j.critrevonc.2015.07.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Syed YY, McKeage K. Aflibercept: A review in metastatic colorectal cancer. Drugs. 2015 Aug;75 (12):1435-45.","DOI":"10.1007\/s40265-015-0444-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Karaman S, Lepp\u00e4nen VM, Alitalo K. Vascular endothelial growth factor signaling in development and disease. Dev. 2018;145 (14):1-8.","DOI":"10.1242\/dev.151019"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Guan F, Villegas G, Teichman J, et al. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Physiol. 2006;291 (2):F422-8.","DOI":"10.1152\/ajprenal.00448.2005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF Inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;359 (2):205-7.","DOI":"10.1056\/NEJMc080770"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ollero M, Sahali D. Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol Dial Transplant. 2015;30 (9):1449-55.","DOI":"10.1093\/ndt\/gfu368"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007 Feb;49 (2):186-93.","DOI":"10.1053\/j.ajkd.2006.11.039"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Pfister F, Amann K, Daniel C, et al. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;990-1001.","DOI":"10.1111\/his.13716"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Person F, Rinschen MM, Brix SR, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32 (5):684-700.","DOI":"10.1038\/s41379-018-0186-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hanna RM, Barsoum M, Arman F, et al. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96 (3):572-80.","DOI":"10.1016\/j.kint.2019.02.042"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Touzani F, Geers C, Pozdzik A. Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury. Case Reports Nephrol. 2019;2019:1-4.","DOI":"10.1155\/2019\/2919080"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hanna RM, Tran N-T, Patel SS, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use. Front Med [Internet]. 2020;7:579603. Available from: https:\/\/doi.org\/10.3389\/fmed.2020.579603","DOI":"10.3389\/fmed.2020.579603"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Fujii T, Kawasoe K, Tonooka A, et al. Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review. Medicine (Baltimore) [Internet]. 2019 Jul;98 (27):e16236. Available from: https:\/\/doi.org\/10.1097\/MD.0000000000016236","DOI":"10.1097\/MD.0000000000016236"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yamada R, Okawa T, Matsuo K, et al. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol. 2019 Jan 11;20 (1):14.","DOI":"10.1186\/s12882-018-1194-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sendeyo K, Audard V, Zhang S, et al. Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. Kidney Int. 2013 Mar;83 (3):414-25.","DOI":"10.1038\/ki.2012.426"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yu L, Lin Q, Feng J, et al. Inhibition of nephrin activation by c-mip through Csk-Cbp-Fyn axis plays a critical role in Angiotensin II-induced podocyte damage. Cell Signal. 2013 Mar;25 (3):581-8.","DOI":"10.1016\/j.cellsig.2012.11.017"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Izzedine H, Mangier M, Ory V, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int. 2014;85 (2):457-70.","DOI":"10.1038\/ki.2013.344"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nowak DE, Tian B, Jamaluddin M, et al. RelA Ser276 Phosphorylation is required for activation of a subset of NF-\u03baB-dependent genes by recruiting cyclin-dependent kinase 9\/cyclin T1 complexes. Mol Cell Biol. 2008;28 (11):3623-38.","DOI":"10.1128\/MCB.01152-07"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Maruyama K, Nakagawa N, Suzuki A, et al. Pazopanib-induced endothelial injury with podocyte changes. Intern Med. 2018;57 (7):987-91.","DOI":"10.2169\/internalmedicine.9576-17"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Boll\u00e9e G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009 Feb;24 (2):682-5.","DOI":"10.1093\/ndt\/gfn657"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ruebner RL, Copelovitch L, Evageliou NF, et al. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol. 2014 May;29 (5):863-9.","DOI":"10.1007\/s00467-013-2696-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Maruyama K, Chinda J, Kuroshima T, et al. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med. 2015;54 (7):823-6.","DOI":"10.2169\/internalmedicine.54.3661"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Masutani K, Fujisaki K, Maeda H, et al. Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol. 2008 Oct;12 (5):398-402.","DOI":"10.1007\/s10157-008-0066-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kaneko T, Shimizu A, Aoki M, et al. A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN case reports. 2015 May;4 (1):31-7.","DOI":"10.1007\/s13730-014-0135-0"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007 May;8 (5):387-94.","DOI":"10.1016\/S1470-2045(07)70108-0"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Manohar S, Bansal A, Wanchoo R, et al. Ibrutinib induced acute tubular injury: A case series and review of the literature. Am J Hematol. 2019;94 (9):E223-5.","DOI":"10.1002\/ajh.25546"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mark\u00f3th C, File I, Sz\u00e1sz R, et al. Ibrutinib-induced acute kidney injury via interstitial nephritis. Ren Fail. 2021;43 (1):335-9.","DOI":"10.1080\/0886022X.2021.1874985"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17 (1):1-23.","DOI":"10.1186\/s12943-018-0779-z"},{"issue":"1","key":"40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"40. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39 (1):1-10.","journal-title":"Immunity","ISSN":"https:\/\/id.crossref.org\/issn\/1074-7613","issn-type":"print"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50 (12):1-11.","DOI":"10.1038\/s12276-018-0191-1"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1\/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19 (19):5300-9.","DOI":"10.1158\/1078-0432.CCR-13-0143"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: Tumor escape from the immune system. Cancer Immunol Immunother. 2011;60 (8):1161-71.","DOI":"10.1007\/s00262-011-1012-8"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Franciszkiewicz K, Boissonnas A, Boutet M, Combadi\u00e8re C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 2012 Dec 15;72 (24):6325-32.","DOI":"10.1158\/0008-5472.CAN-12-2027"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways. Am J Clin Oncol. 2016;39 (1):98-106.","DOI":"10.1097\/COC.0000000000000239"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One [Internet]. 2016;11 (7):e0160221. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0160221","DOI":"10.1371\/journal.pone.0160221"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Jamal S, Hudson M, Fifi-Mah A, et al. Immune-related adverse events associated with cancer immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020;47 (2):166-75.","DOI":"10.3899\/jrheum.190084"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Ann Oncol. 2017;28 (10):2377-85.","DOI":"10.1093\/annonc\/mdx286"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90 (3):638-47.","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Meraz-Mu\u00f1oz A, Amir E, Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: Incidence, risk factors and outcomes. J Immunother Cancer. 2020;8 (1):1-9.","DOI":"10.1136\/jitc-2019-000467"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Izzedine H, Mathian A, Champiat S, et al. Renal toxicities associated with pembrolizumab. Clin Kidney J. 2019;12 (1):81-8.","DOI":"10.1093\/ckj\/sfy100"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Shingarev R, Glezerman IG. Kidney complications of immune checkpoint inhibitors: A review. Am J Kidney Dis. 2019;74 (4):529-37.","DOI":"10.1053\/j.ajkd.2019.03.433"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: A narrative review. Am J Nephrol. 2017;45 (2):160-9.","DOI":"10.1159\/000455014"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Gallan AJ, Alexander E, Reid P, et al. Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors. Am J Kidney Dis. 2019;74 (6):853-6.","DOI":"10.1053\/j.ajkd.2019.04.016"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7 (1).","DOI":"10.1186\/s40425-018-0478-8"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010 Jul;236:219-42.","DOI":"10.1111\/j.1600-065X.2010.00923.x"},{"issue":"2","key":"57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13730-017-0269-y","volume":"6","author":"A Uchida","year":"2017","unstructured":"57. Uchida A, Watanabe M, Nawata A, et al. Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN Case Reports. 2017;6 (2):169-74.","journal-title":"CEN Case Reports","ISSN":"https:\/\/id.crossref.org\/issn\/2192-4449","issn-type":"print"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Murakami N, Borges TJ, Yamashita M, et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9 (3):411-7.","DOI":"10.1093\/ckj\/sfw024"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Belliere J, Meyer N, Mazieres J, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115 (12):1457-61.","DOI":"10.1038\/bjc.2016.358"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Escandon J, Peacock S, Trabolsi A, et al. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer. 2017;5 (1):1-6.","DOI":"10.1186\/s40425-016-0205-2"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Cassol C, Satoskar A, Lozanski G, et al. Anti\u2212PD-1 Immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Reports. 2019;4 (8):1152-60.","DOI":"10.1016\/j.ekir.2019.06.001"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol. 2016;17 (1):1-6.","DOI":"10.1186\/s12882-016-0408-2"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Kidd JM, Gizaw AB. Ipilimumab-associated minimal-change disease. Kidney Int. 2016;89 (3):720.","DOI":"10.1016\/j.kint.2015.11.028"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Charmetant X, Teuma C, Lake J, et al. A new expression of immune checkpoint inhibitors' renal toxicity: When distal tubular acidosis precedes creatinine elevation. Clin Kidney J. 2019;13 (1):42-5.","DOI":"10.1093\/ckj\/sfz051"},{"issue":"7","key":"65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1445952","volume":"7","author":"M Xipell","year":"2018","unstructured":"65. Xipell M, Victoria I, Hoffmann V, et al. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. Oncoimmunology. 2018;7 (7):1-5.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Nunes AT, Annunziata CM. Proteasome inhibitors: structure and function. Semin Oncol. 2017 Dec;44 (6):377-80.","DOI":"10.1053\/j.seminoncol.2018.01.004"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Portuguese AJ, Gleber C, Passero FC, et al. A review of thrombotic microangiopathies in multiple myeloma. Leuk Res [Internet]. 2019 Oct;85:106195. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619301407","DOI":"10.1016\/j.leukres.2019.106195"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016;91 (9):E348-52.","DOI":"10.1002\/ajh.24447"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Moore H, Romeril K. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J. 2011 Apr;41 (4):348-50.","DOI":"10.1111\/j.1445-5994.2011.02458.x"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J. 2014;7 (1):11-22.","DOI":"10.1093\/ckj\/sft135"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Abbas A, Mirza MM, Ganti AK, et al. Renal toxicities of targeted therapies. Target Oncol. 2015 Dec 30;10 (4):487-99.","DOI":"10.1007\/s11523-015-0368-7"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Izzedine H, Escudier B, Rouvier P, et al. Acute tubular necrosis associated with mTOR inhibitor therapy: A real entity biopsy-proven. Ann Oncol. 2013;24 (9):2421-5.","DOI":"10.1093\/annonc\/mdt233"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Nicolaysen A. Nephrotoxic chemotherapy agents: old and new. Adv Chronic Kidney Dis. 2020;27 (1):38-49.","DOI":"10.1053\/j.ackd.2019.08.005"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/2\/89_JNMS.2022_89-221\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:44:05Z","timestamp":1715233445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/2\/89_JNMS.2022_89-221\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2022_89-221","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"JNMS.2022_89-221"}}